Drug maker Aurobindo Pharma Ltd today said the company has received final approval from the US health regulator to manufacture and market Quinapril tablets in the American market.
The company has received the approval from the US Food and Drug Administration (USFDA) to manufacture the drug, which is indicated for the treatment of hypertension and falls under the cardiovascular (CVS) therapeutic category, in strengths of 5mg, 10mg, 20mg and 40mg (ANDA 202725), it said in a release.
The market size of the product is estimated to be USD 49 million for the 12 months ended September 2012, according to IMS, it said. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, it said. Aurobindo now has a total of 188 ANDA approvals (161 final approvals including 4 from Aurolife Pharma LLC and 27 tentative approvals) from USFDA, the release added. Shares of Aurobindo were quoting at Rs 187.70 apiece, down 2.24 per cent, in the late afternoon trade on the BSE.
Aurobindo Pharm stock price
On November 27, 2015, Aurobindo Pharma closed at Rs 818.30, down Rs 6.4, or 0.78 percent. The 52-week high of the share was Rs 1540.55 and the 52-week low was Rs 490.50.
The company's trailing 12-month (TTM) EPS was at Rs 25.30 per share as per the quarter ended September 2015. The stock's price-to-earnings (P/E) ratio was 32.34. The latest book value of the company is Rs 94.68 per share. At current value, the price-to-book value of the company is 8.64.
Set email alert for
ADS BY GOOGLE
video of the day
Dont see mkt going anywhere now; like Bharat Forge: Dipen